UroGen Pharma Ltd. Ordinary Shares
Symbol: URGN (NASDAQ)
Company Description:
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
- Today's Open: $0
- Today's High: $0
- Today's Low: $0
- Today's Volume: 0
- Yesterday Close: $19.11
- Yesterday High: $20.938
- Yesterday Low: $18.45
- Yesterday Volume: 1.67M
- Last Min Volume: 0
- Last Min High: $0
- Last Min Low: $0
- Last Min VWAP: $0
- Name: UroGen Pharma Ltd. Ordinary Shares
- Website: https://www.urogen.com
- Listed Date: 2017-05-04
- Location: RA'ANANA, L3
- Market Status: Active
- CIK Number: 0001668243
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $884.11M
- Round Lot: 100
- Outstanding Shares: 46.26M
- Asset Type: CS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-09 | 4 | View |
| 2025-09-09 | 4 | View |
| 2025-09-09 | 144 | View |
| 2025-09-09 | 144 | View |
| 2025-08-27 | 4 | View |
| 2025-08-27 | 4 | View |
| 2025-08-27 | 4 | View |
| 2025-08-27 | 4 | View |
| 2025-08-27 | 4 | View |
| 2025-08-27 | 4 | View |
| 2025-08-27 | 8-K | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-13 | 4 | View |
| 2025-08-12 | SCHEDULE 13G | View |
| 2025-08-07 | 10-Q | View |
| 2025-08-07 | 8-K | View |
| 2025-08-06 | SCHEDULE 13G | View |
| 2025-08-05 | SCHEDULE 13G/A | View |
| 2025-07-30 | 4 | View |
| 2025-07-30 | 4 | View |